Crinetics Pharmaceuticals (CRNX) Equity Income (2022 - 2024)
Crinetics Pharmaceuticals' quarterly Equity Income came in at -$470000.0 in Q1 2024, up 88.81% quarter-over-quarter from -$4.2 million in Q4 2023.
Crinetics Pharmaceuticals has reported Equity Income for 3 years, with the latest figure at -$470000.0 in Q1 2024.
- For the quarter ending Q1 2024, Equity Income changed N/A year-over-year to -$470000.0; the trailing twelve-month figure through Dec 2024 stood at -$470000.0 (up 90.96% YoY), and the FY2024 full-year result was -$470000.0, up 90.96% from the prior year.
- Equity Income for Q1 2024 stood at -$470000.0, up from -$4.2 million in the prior quarter.
- The five-year high for Equity Income was -$470000.0 in Q1 2024, with the low at -$4.2 million in Q4 2023.
- Average Equity Income over 3 years is -$1.7 million, with a median of -$1.0 million recorded in 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Crinetics Pharmaceuticals | 3.59 Bn | 3.59 Bn | 10.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -470,000.00 |
| Dec 31, 2023 | -4.20 Mn |
| Sep 30, 2023 | -997,000.00 |
| Mar 31, 2022 | -1.01 Mn |